- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
- Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
- Open Cosmos Takes First Major Step Towards Its Low Earth Orbit Constellation With Landmark Satellite Launch
- Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
- Global Mass Spectrometry Market Set to Reach USD 10.56 Billion by 2031: Asia-Pacific's Double-Digit Growth Underscores Emerging Opportunities
- $22.41 Bn Bioprocess Automation Market Forecast to 2033: Rising Demand for Biologics, Advancements in AI and Robotics, and a Heightened Emphasis on Regulatory Compliance
- AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection
- Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement
- First-of-its-kind Trojan Horse Cancer Treatment Approved for Clinical Trials
